Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 20/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 18/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pf-04455242 SCHEMBL3212512 | 1.00 | OPRK1 (1.00) | OPRK1OPRM1KCNH2 | |
| Pf-04455242 SCHEMBL29484946 | 0.99 | OPRK1 (0.98) | OPRK1OPRM1KCNH2 | |
| SCHEMBL3213443 | 0.83 | OPRK1 (0.77) | OPRK1OPRM1KCNH2 | |
| SCHEMBL3219508 | 0.83 | OPRK1 (0.77) | OPRK1OPRM1KCNH2 | |
| SCHEMBL3219520 | 0.83 | OPRK1 (0.77) | OPRK1OPRM1KCNH2 | |
| SCHEMBL3212478 | 0.81 | OPRK1 (0.68) | OPRK1OPRM1KCNH2 | |
| SCHEMBL3219537 | 0.80 | OPRK1 (1.00) | OPRK1OPRM1KCNH2 | |
| SCHEMBL3204687 | 0.79 | OPRK1 (1.00) | OPRK1OPRM1KCNH2 | |
| SCHEMBL3214852 | 0.79 | OPRK1 (0.79) | OPRK1OPRM1KCNH2 | |
| SCHEMBL3225463 | 0.78 | OPRK1 (1.00) | OPRK1OPRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024178082-A2 | COMPOSITION OF OPIOID RECEPTOR MODULATOR AND MDMA FOR USE THEREOF | FREEDOM BIOSCIENCES, INC. (US) | 2024-08-29 | — | — | WO | claimed |
| EP-4574210-A2 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | The Scripps Research Institute (US) | 2025-06-25 | — | — | EP | disclosed |
| EP-4141001-B1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | SCRIPPS RESEARCH INST (US) | 2025-03-05 | — | — | EP | disclosed |
| US-20240343719-A1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | Neumora Therapeutics, Inc. | 2024-10-17 | — | — | US | disclosed |
| WO-2024178082-A2 | COMPOSITION OF OPIOID RECEPTOR MODULATOR AND MDMA FOR USE THEREOF | FREEDOM BIOSCIENCES, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| CN-110914262-B | Kappa opioid receptor antagonists and products and methods relating thereto | 斯克里普斯研究所 | 2024-04-05 | — | — | CN | disclosed |
| US-11897873-B2 | Kappa opioid receptor antagonists and products and methods related thereto | BLACKTHORN THERAPEUTICS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| EP-4141001-A1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | The Scripps Research Institute (US) | 2023-03-01 | — | — | EP | disclosed |
| EP-3596069-B1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | SCRIPPS RESEARCH INST (US) | 2022-07-13 | — | — | EP | disclosed |
| US-20220162202-A1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | Neumora Therapeutics, Inc. | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162202-A1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885OPRM1 3/4885KCNH2 553/4885 |
| US-20240343719-A1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885OPRM1 3/4885KCNH2 571/4885 |
| US-11897873-B2 | Kappa opioid receptor antagonists and products and methods related thereto | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885OPRM1 3/4885KCNH2 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.